Paul Miranda, MD

Board-Certified in Family Medicine · Emergency Physician · Obesity Medicine Association member

I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.

Medically reviewed by Paul Miranda, MD

If you’re in Chattanooga typing “Ro vs compounded semaglutide clinic” into Google, you’re probably holding two numbers that don’t match and wondering why. I’m Dr. Paul Miranda, board-certified, and I practice telehealth weight-loss medicine from right here in Chattanooga — not from a call center in another state. I personally review every chart before a patient at Summit Metabolic Health starts semaglutide. That one fact is the actual difference between Ro and a clinic like this, and it’s worth understanding before you pick either one.

Ro’s pitch is speed: fill out a form, get routed to a clinician, get approved same-day. What the landing page doesn’t lead with is that Ro exited compounded semaglutide entirely. Today Ro sells branded Wegovy or Ozempic only, at roughly $448 to $498 a month, all-in. There’s no lower tier to fall back into. You pay the branded rate or you leave the platform.

That price isn’t a teaser that creeps up later. It’s the floor. And Ro has been flagged as non-physician-led — the clinician reviewing your intake form is frequently an NP or PA working through a queue, not a physician reading your specific history before deciding your dose.

Ro’s exit from compounded GLP-1s wasn’t a quiet product update. It happened alongside a securities-fraud lawsuit filed in October 2026, alleging the company’s model issued prescriptions within minutes, without a genuine consult behind them. I’m not going to pretend to know how that case resolves. But the underlying allegation — that approval moved faster than a real evaluation could — tracks with what the business model always was: volume first, chart review second, if at all.

For your bill, the practical result is simple. The affordable option is gone. What’s left is branded pricing with a legal cloud over how the prescribing actually happened. If you started with Ro during its compounded era, it’s worth checking your current invoice against your first one — the gap is usually larger than people remember agreeing to.

Semaglutide is not a mild drug, and the trial data makes the case for real oversight better than I can. In STEP 1 (Wilding et al., NEJM, 2021), patients on semaglutide 2.4mg lost a mean 14.9% of body weight at 68 weeks, against 2.4% on placebo. That’s a large effect — large enough that how you get there matters.

SELECT (Lincoff et al., NEJM, 2023) matters even more to how I think about this. In adults with established cardiovascular disease, semaglutide cut major adverse cardiac events — heart attack, stroke, cardiovascular death — by 20%, independent of diabetes status. I work ER shifts. I see what happens when a medication this powerful is titrated on a fixed schedule instead of a monitored one: nausea nobody adjusted for, a dose increase that outran what someone’s gut could tolerate, a cardiac history nobody asked about before approving the next step up. A drug that moves appetite, gastric emptying, and measurable cardiac risk by this much isn’t a formality to rubber-stamp. It’s a reason dose titration needs a physician actually watching, not an app advancing you on a calendar.

Here’s what a visit at Summit actually looks like, because “physician-reviewed” shouldn’t be a slogan you have to take on faith. I read your intake myself — prior medications, labs if you have them, your history, anything that should change your starting dose before I set it. I don’t run every patient up the manufacturer’s fastest titration schedule. I hold doses longer than the label requires, target a controlled 1 to 1.5 pounds a week instead of the fastest number the drug allows, and build in a dose hold roughly every 25 pounds lost. At goal weight, the dose tapers down instead of stopping on a cliff.

Medication is compounded through a licensed 503A pharmacy — same active ingredient as the branded pen, different manufacturing pathway, none of the direct-to-consumer markup. That’s the whole reason Summit’s compounded program runs $135 to $225 a month instead of Ro’s $448 to $498. I went through the exact pricing math, pharmacy to pharmacy, in Ro vs. Compounded Semaglutide in Chattanooga: What You Actually Pay — that post is the numbers; this one is why the numbers aren’t the whole story.

Month one, the gap already shows. Ro’s form-based approval can clear you same-day with no visit and no exam. At Summit, I’m reading your actual chart before your first dose is set, which can take a little longer but means the starting dose is chosen for you, not assigned by default.

Month two through six is where the models diverge further. Ro’s price doesn’t move with your dose — branded pricing is branded pricing, flat regardless of where you are in titration. Summit’s compounded pricing stays in that $135 to $225 band as your dose climbs, and if a side effect shows up, you’re messaging the same physician who set your plan, not reopening a ticket into a rotating NP queue. This is the same gap I laid out in more detail in Physician-Supervised Care vs. the Telehealth Mill Model — Ro is one version of the pattern, not the exception to it.

At goal weight, the difference is starkest. Ro has no built-in exit plan; the subscription just keeps billing at the branded rate until you cancel. At Summit, tapering to the lowest dose that holds your weight is part of the plan from day one, not an afterthought you have to request.

Before you commit a card number to Ro, Summit, or anywhere else, ask yourself five questions:

– Did an actual physician review my chart, or did a form route me to whoever’s next in a queue? – Is my price tied to my dose, or to a branded subscription that never moves? – Who do I reach when a side effect shows up — the same clinician, or a new name every time? – Is my medication compounded or branded, and does that change what I’m actually paying for? – Is there a plan for when I reach goal weight, or does the billing just continue?

Ro can answer “fast.” It’s had a harder time answering the rest, and the October 2026 lawsuit is exactly about that gap — a model built to approve quickly facing a claim that it skipped the consult it was supposed to be running. No telehealth provider, including Summit, should ask you to take “legit” on faith. You should be able to name your physician and verify what you’re paying for. You can read more of what I’ve written on this across the Summit blog.

The honest caveat: trial averages are group data, not a promise about your specific result, and semaglutide needs monitoring no matter where it’s sourced. But between a branded-only subscription with a fraud suit attached and a physician-reviewed compounded program in your own city, this isn’t a close call. Ready to start? Apply at summitmetabolichealth.com/apply.

This post is for educational purposes and does not replace individualized medical care. Group trial averages are not a promise about your results.